CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Panbela Therapeutics Inc   (PBLA)
Other Ticker:  
 

Panbela Therapeutics Inc 's Total Debt to Equity

PBLA's quarterly Total Debt to Equity and Total Debt, Equity growth




PBLA Total Debt to Equity (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity Change - -61.48 % - - -
Y / Y Total Debt Change -28.23 % - - - -
Total Debt to Equity MRQ 0.87 1.65 - - -
Overall Ranking # 1685 # 1940 # 0 # 0 # 0
Seq. Equity Change 89.43 % - - - -
Seq. Total Debt Change 0 % -38.72 % 17.11 % 0 % -

New: More PBLA's historic Total Debt to Equity Ratios >>


Comment on PBLA Total Debt to Equity in the second quarter 2023
Due to debt repayement of 0% Panbela Therapeutics Inc improved Total Debt to Equity in second quarter 2023 to 0.87, above the Panbela Therapeutics Inc 's average Total Debt to Equity.

Within Major Pharmaceutical Preparations industry in the second quarter 2023, 93 other companies have achieved lower Total Debt to Equity than Panbela Therapeutics Inc in the II Quarter 2023. While Total Debt to Equity total ranking has improved so far in the second quarter 2023 to 1685, from total ranking in the first quarter 2023 at 1940.

Explain Debt to Equity Ratio?
What is the structure of PBLA´s Total Debt?
How valuable is the PBLA´s Equity?
Total Debt to Equity second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 94
Healthcare Sector # 249
Overall Market # 1685


Total Debt to Equity Statistics
High Average Low
2.73 0.86 0.01
(Jun 30 2018)   (Sep 30 2020)




Financial Statements
Panbela Therapeutics Inc 's Equity $ 5 Millions Visit PBLA's Balance sheet
Panbela Therapeutics Inc 's Total Debt $ 4 Millions Visit PBLA's Balance sheet
Source of PBLA's Sales Visit PBLA's Sales by Geography


Cumulative Panbela Therapeutics Inc 's Total Debt to Equity

PBLA's Total Debt to Equity for the trailling 12 Months

PBLA Total Debt to Equity

 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity TTM Growth - -61.48 % - - -
Y / Y Total Debt TTM Growth -28.23 % - - - -
Total Debt to Equity TTM - - - 3.18 0.23
Total Ranking TTM # 1822 # 2546 # 0 # 1593 # 1011
Seq. Equity TTM Growth 89.43 % - - - -
Seq. Total Debt TTM Growth 0 % -38.72 % 17.11 % 0 % -

Debt to equity ratio ranking by company, industry and sector >> Back to PBLA Financial Strength Comparisons >> Go to Compare PBLA Total Debt to Equity Ratio to its Competitors

TTM Total Debt to Equity Comment
On the trailing twelve months basis Due to debt repayement of 0% Panbela Therapeutics Inc improved Total Debt to Equity in the 12 months ending in II Quarter 2023 to -2.34, below the company's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 93, during the past 12 months, other companies have achieved lower Total Debt to Equity than Panbela Therapeutics Inc . While Total Debt to Equity total ranking has improved so far to 1822, from total ranking in previous 12 month period at 2546.

Explain Debt to Equity Ratio?
What is the structure of PBLA´s Total Debt?
How valuable is the PBLA´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 94
Healthcare Sector # 249
Within the Market # 1685


TTM Total Debt to Equity Statistics
High Average Low
2.73 0.86 0.01
(Jun 30 2018)   (Sep 30 2020)




Companies with similar Total Debt to Equity in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Total Debt to EquityJun 30 2023 MRQ Total DebtJun 30 2023 MRQ Equity
Tempest Therapeutics Inc   2.09 $ 10.458  Millions$ 5.012  Millions
Corbus Pharmaceuticals Holdings Inc   1.93 $ 18.387  Millions$ 9.521  Millions
Kala Bio inc   1.92 $ 33.569  Millions$ 17.492  Millions
Eli Lilly And Company  1.69 $ 18,820.000  Millions$ 11,149.300  Millions
Phibro Animal Health Corporation  1.68 $ 474.836  Millions$ 282.509  Millions
Sarepta Therapeutics Inc   1.67 $ 1,235.517  Millions$ 741.411  Millions
Iterum Therapeutics Plc  1.64 $ 11.666  Millions$ 7.129  Millions
Jazz Pharmaceuticals Plc  1.62 $ 5,717.646  Millions$ 3,525.675  Millions
Trevena inc   1.45 $ 14.176  Millions$ 9.782  Millions
Zoetis Inc   1.42 $ 6,557.000  Millions$ 4,621.000  Millions
Alimera Sciences Inc   1.38 $ 63.954  Millions$ 46.230  Millions
Eyenovia inc   1.34 $ 14.124  Millions$ 10.522  Millions
Marinus Pharmaceuticals Inc   1.26 $ 71.986  Millions$ 57.339  Millions
Capricor Therapeutics inc   1.24 $ 3.376  Millions$ 2.731  Millions
Milestone Pharmaceuticals Inc   1.19 $ 48.073  Millions$ 40.408  Millions
Bristol myers Squibb Company  1.18 $ 37,676.000  Millions$ 32,030.000  Millions
Rockwell Medical inc   0.98 $ 9.371  Millions$ 9.528  Millions
Cerevel Therapeutics Holdings Inc   0.96 $ 336.446  Millions$ 350.500  Millions
Madrigal Pharmaceuticals Inc   0.96 $ 99.249  Millions$ 103.506  Millions
Merck and Co Inc   0.95 $ 36,911.000  Millions$ 38,742.000  Millions
Emergent Biosolutions Inc   0.94 $ 903.200  Millions$ 956.300  Millions
Biovie Inc   0.93 $ 14.332  Millions$ 15.340  Millions
Viatris Inc   0.89 $ 18,603.600  Millions$ 20,843.300  Millions
Prestige Consumer Healthcare Inc   0.89 $ 1,316.711  Millions$ 1,480.295  Millions
G1 Therapeutics Inc   0.89 $ 50.936  Millions$ 57.548  Millions
Panbela Therapeutics Inc   0.87 $ 4.194  Millions$ 4.802  Millions
Amphastar Pharmaceuticals Inc   0.85 $ 501.200  Millions$ 589.235  Millions
Perrigo Company Plc  0.84 $ 4,094.300  Millions$ 4,848.600  Millions
Orgenesis Inc   0.84 $ 20.178  Millions$ 23.965  Millions
Ibio inc   0.84 $ 12.937  Millions$ 15.381  Millions

Date modified: 2023-08-11T16:51:33+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com